AFTX-201
Asset
Delivers a functional BAG3 gene to restore BAG3 protein expression in heart muscle cells.
- Stage
- Phase 1
- Modality
- Gene therapy
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2BAG3 mutation associated dilated cardiomyopathy
Phase 1, Recruiting, NCT07426419, clinicaltrials.gov, Oct 17, 2026
Dilated cardiomyopathy
Phase 1, Recruiting, NCT07426419, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors1
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.